MINERVA IMAGING ApS

Egen beskrivelse på virk.dk

Description of key activities of the companyMinerva Imaging’s vision is to become the leading contract research and contract development organization for targeted radionuclide therapy, enabling improved treatment regimens for cancer patients with a focus on the use of advanced animal models within oncology and cardiovascular diseases and in vivo molecular imaging for translational research and drug development. We aim to excel in delivering customized cancer radiopharmaceutical research and serve as an extended research team to our collaborators. We have built a global leading R&D platform for targeted radionuclide therapy and Contract Development and Manufacturing (CDMO) to enable integrated planning and faster execution of promising new radionuclide theragnostic projects in close collaboration with leading researchers, biotech, and pharmaceutical companies. Minerva is at the forefront of R&D in the theragnostic area. We are in a very fast-paced environment, where our researchers directly impact the advancement of new improved, and lifesaving drugs for seriously ill cancer patients. We have the ambition to make a difference for our clients, collaborating on advancing new treatment modalities for patients.